Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer

Trial Profile

Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2012

At a glance

  • Drugs Gemcitabine; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 08 Jun 2012 ClinicalTrials.gov record integrated.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top